anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Local anesthesia is an essential procedure in the comprehensive treatment of pediatric patients. In the treatment of subjects with dental disease and infection, local anesthesia is commonly required when performing operative procedures. The use of local anesthesia serves two main purposes: (i) enables the patient to remain free of discomfort during the sometimes painful procedure and (ii) permits the practitioner to complete the procedure without fear of hurting the patient which might otherwise impede the practitioner's ability to provide comprehensive care. However, patients are often fearful of local anesthesia because traditional preparations of local anesthesia are acidic and can be painful. Thus, an important advance in the areas of subject management and pain control during operative procedures would be a preparation of local anesthesia that significantly reduced the pain upon injection. A 2010 Cochrane Review found that adjusting the pH of lidocaine with sodium bicarbonate reduced the pain of injection for both adults and children. In this study, we will compare two local anesthetic preparations, a buffered anesthetic and the conventionally available anesthetic, for pain upon injection.

The study will test a local anesthetic buffering system, the Onset system, an FDA Class 1 compounding device manufactured by Onpharma Inc. It is a simple and portable local anesthesia buffering system that compounds anesthetic solution and 8.4% sodium bicarbonate neutralizing additive solution in a precise manner that brings the anesthetic solution up to human physiologic pH. Commercially available local anesthetics have a low pH to allow for prolonged shelf life, and to keep the anesthetic molecules in solution. The combination of a buffering sodium bicarbonate agent and local anesthetic has been reported to result in pain-free injections for both adults and children. The neutralizing additive solution is a sterile, nonpyrogenic, solution of sodium bicarbonate (NaHCO3) in water. pH is adjusted with carbon dioxide. Sodium Bicarbonate Inj., 8.4% USP Neutralizing Additive Solution (NDC Code 509-100-03) and Lidocaine w/ Epinephrine are compatible. Sodium bicarbonate is used in medicine and dentistry as regularly as saline, and pre-dates the FDA. It is commercially available and currently being used by health professionals in the U.S.A.

The local anesthetic used in the study will be 2% lidocaine with 1:100,000 ppm epinephrine, part of the amide family of local anesthetics. It has been widely used in dentistry and medicine and has long-standing proven records of safety.
BACKGROUND: For patients on dialysis with poor quality of life and prognosis, dialysis withdrawal and subsequent transition to palliative care is recommended. This study aims to understand multi-stakeholder perspectives regarding dialysis withdrawal and identify their information needs and support for decision-making regarding withdrawing from dialysis and end-of-life care.
METHODS: Participants were recruited through purposive sampling from eight dialysis centers and two public hospitals in Singapore. Semi-structured in-depth interviews were conducted with 10 patients on dialysis, 8 family caregivers, and 16 renal healthcare providers. They were held in-person at dialysis clinics with patients and caregivers, and virtually via video-conferencing with healthcare providers. Interviews were audio-recorded, transcribed, and thematically analyzed. The Ottawa Decision Support Framework's decisional-needs manual was used as a guide for data collection and analysis, with two independent team members coding the data.
RESULTS: Four themes reflecting perceptions and support for decision-making were identified: a) poor knowledge and fatalistic perceptions; b) inadequate resources and support for decision-making; c) complexity of decision-making, unclear timing, and unpreparedness; and d) internal emotions of decisional conflict and regret. Participants displayed limited awareness of dialysis withdrawal and palliative care, often perceiving dialysis withdrawal as medical abandonment. Patient preferences regarding decision-making ranged from autonomous control to physician or family-delegated choices. Cultural factors contributed to hesitancy and reluctance to discuss end-of-life matters, resulting in a lack of conversations between patients and providers, as well as between patients and their caregivers.
CONCLUSIONS: Decision-making for dialysis withdrawal is complicated, exacerbated by a lack of awareness and conversations on end-of-life care among patients, caregivers, and providers. These findings emphasize the need for a culturally-sensitive tool that informs and prepares patients and their caregivers to navigate decisions about dialysis withdrawal and the transition to palliative care. Such a tool could bridge information gaps and stimulate meaningful conversations, fostering informed and culturally aligned decisions during this critical juncture of care.
PROBLEM TO BE SOLVED: To prepare the subject agent having high safety without any adverse effects by using an extract of a specific plan having antillergic actions based on chemical mediator liberation inhibiting actions from a mastycyute and a basocyte as an active ingredient. SOLUTION: This therapeutic agent comprises one or more selected from an extract from a plant of the genus Coix [preferably Coix lachryma-jobi var. ma-yuen (Roman.) Stapf.], an extract from a plant of the family Saururaceae [preferably Huttuynia cordate Tedicineunb. Saururus chineses (Lour.) Baill. or Hottuynia Herba] and an extract from a plant of the geus Tilia [preferably a flower of Tilia japonica (Miq.) Simonk.] as an active ingredient. The chemical mediator is preferably histamine, serotonin or leukotriene. The daily dose of the plant extract when utilized as a medicine is 5-500mg expressed in terms of dry weight in the case of oral administration. The concentration thereof when formulated in a food or a cosmetic is preferably 0.001-20wt.%.
OBJECTIVES: I. Determine the rates of hematologic and immune reconstitution in pediatric patients with high risk hematologic malignancies in first remission or in second or subsequent remission, and adult patients with acute lymphocytic leukemia (ALL) or acute nonlymphocytic leukemia (ANLL) in second or subsequent remission, who are undergoing high dose chemoradiotherapy followed by unrelated umbilical cord blood (UCB) transplantation. II. Determine the incidence of graft-versus-host disease in this setting. III. Determine whether contamination of umbilical cord blood with maternal cells is a clinical problem in this setting. IV. Describe the incidence of leukemic relapse in these patients after UCB transplantation. V. Describe the incidence of serious infections and secondary lymphoproliferative diseases following transplantation with UCB in these patients. VI. Determine specifically whether larger recipients (greater than 40 kg) can be durably engrafted with unrelated UCB, and determine whether nucleated cell or progenitor cell content of the graft is predictive of hematological engraftment.

OUTLINE: Patients undergo a back-up bone marrow harvest prior to treatment. Patients receive 9 fractions of total body irradiation (TBI) on days -9 to -5, followed by melphalan IV on days -4 to -2 and antithymocyte globulin IV or methylprednisolone IV on days -3 to -1. If TBI is not allowed, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5. On day 0, patients receive umbilical cord blood infusion. Cyclosporine and methylprednisolone begin on day -2 and continue for 6 months. Patients are followed indefinitely for survival and late toxicity.

PROJECTED ACCRUAL: A minimum of 48 patients will be accrued into this study within 4 years.
Recruitment to this trial will be stratified by donor type as HLA (human leukocyte antigen) matched sibling, matched unrelated donor or umbilical cord blood. Patients will be conditioned with a myeloablative regimen such as, but not limited to, total body irradiation and cyclophosphamide. The donor stem cell grafts will come from mobilized peripheral blood of 8/8 or 7/8 HLA-identical family members, 8/8 (HLA A, B, C, DRBeta1) allele-level matched unrelated donors, or dual umbilical cord blood grafts with at least 4 of 6 HLA matching at HLA A and B (low resolution) and DRBeta1 (at high resolution). The target CD34+ cell dose will be 5 X 10(6)/kg recipient ideal body weight. For HLA matched sibling or matched unrelated donor (MUD) transplants, all patients will receive a minimum of 2 X 10(6) CD 24+ cells/kg. For cord blood transplants, each unit will contain a minimum total nucleated cell count of of 1.5 X 10(7)/kg. Post-transplant GVHD (graft versus host disease) prophylaxis will be given per institutional standard.
Participants receive daratumumab IV on days 1, 8, 15, and 22, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may receive up to 8 courses at the discretion of treating physician.
Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g intravenously (IV)/per oral (PO) q6 hours in the first 48 hours, and Acetaminophen 1g PO q6 hours thereafter; 2. Ketorolac 30mg IV once and Celebrex 200mg PO q12 hours in the first 48 hours, and Naproxen 500mg PO q12 hours thereafter; 3. Tramadol 100mg PO q6 hours in the first 48 hours, and Tramadol 100mg PO q6 hours thereafter; 4. Pregabalin 100mg PO q8 hours in the first 48 hours, and Gabapentin 300mg PO q8 hours thereafter; 5. Lidocaine patch q12 hours in the first 48 hours, and Lidocaine patch q12 hours thereafter; and 6. Opioids (Regional anesthesia) in the first 48 hours, and Opioids and Regional anesthesia thereafter.
Aromatic diisothiocyanates are prepared by dissolving an aromatic primary diamine or a substituted aromatic primary diamine in dimethylformamide, adding to the solution obtained ammonia and carbon disulphide, subjecting the ammonium-bis-dithiocarbamate (or a salt obtained by reacting said salt with another base) thus formed to the action of an alkali metal chlorite and recrystallizing the crude product so obtained from formic acid methyl ester.  The aromatic diamines used as the starting material may contain one or more rings, the individual rings being linked directly to one another or through alkylene groups, or being fused, e.g. phenylene and naphthylene diamines, benzidines and diamino-diphenyl methanes. The abovementioned compounds may be substituted by halogen atoms or alkoxy and/or alkyl groups preferably containing from 1 to 4 carbon atoms.  The reaction between the diamine and the ammonia and carbon disulphide is preferably carried out at low temperatures, e.g. room temperature, and using 2 to 6 mols. of ammonia and 2 to 3 mols. of carbon disulphide per mol. of diamine.  The conversion of the bis-dithiocarbamates into diisothiocyanates may be carried out by stirring an aqueous solution of the alkali metal chlorite into an aqueous solution of the bisdithiocarbamate. Preferably the chlorite solution is of 20% to 40% strength and 2 to 3 mols. of chlorite per mol. of bis-dithiocarbamate are used.  The reaction temperature is advantageously in the range - 15 to + 30 DEG  C. In the examples the following compounds are prepared: phenylene - 1,4 - diisothiocyanate, phenylene - 1,3 - diisothiocyanate, 2 - chloro phenylene - 1,4 - diisothiocyanate, 2 - methoxy-phenylene - 1,4 - diisothiocyanate, 2,6 - dichlorophenylene - 1,4 - diisothiocyante, 2,5 - dimethylphenylene - 1,4 - diisothiocyanate, naphthylene - 1,4 - diisothiocyanate and diphenylene-4,41-diisothiocyanate.
A human lens epithelial cell line capable of expressing an exogeneous immortalizing gene, which is established without infecting with a live virus.  A method for producing the human lens epithelial cell line, which comprises transfecting human lens epithelial cells with an expression vector functionally carrying an exogeneous immortalizing gene, and subculturing said cells in a medium.  The above-mentioned human lens epithelial cell line wherein the cells proliferate in a temperature sensitive manner.  A method for producing a temperature sensitive human lens epithelial cell line, which comprises transfecting human lens epithelial cells with an expression vector functionally carrying an exogeneous immortalizing gene, and subculturing said cells in a medium.  Since the human lens epithelial cell line of the present invention is free of infection with a live virus, the cells are useful as biomaterials.  Moreover, since the temperature sensitive human lens epithelial cell line of the present invention stops proliferation at about 36°C or above, it may be used as a biomaterial for regenerating a human lens.
Wear glasses for correction combined with VR/AR visual training in the first 6 months, and terminate the training for follow-up observation in the last 6 months. Regular follow-up every 3 months, with a total follow-up time of 1 year.
The invention discloses a skin care composition with the effects of suppressing mites and delaying senescence, which at least comprises an oil phase A, a water phase B and a C phase, wherein the C phase comprises a traditional Chinese medicine extract. The traditional Chinese medicine extract is obtained by preparation according to the following method: weighing bulk drugs: 10 to 30 parts of broom cypress fruit by weight, 1 to 10 parts of gardenia by weight and 5 to 20 parts of nutgall by weight; flushing the bulk drugs completely by using water, and mixing; and leaching with the water, filtering, centrifugalizing and taking supernatant. By the confirmation of an experiment, the skin care composition with the effects of suppressing the mites and delaying the senescence has stronger chitinase suppressing capability, can be used for preparing cosmetics and is especially used for preparing cosmetics with the effects of suppressing the mites. The clearance rate to hydroxyl radicals is reinforced along with the increase of the concentration, and the clearance rate can reach more than 80 percent. By proving, a mask provided by the invention has a certain capability of clearing the hydroxyl radicals. Because the hydroxyl radicals are a reason causing the senescence, the effect of clearing the hydroxyl radicals is mainly represented in the function of delaying the senescence. Moreover, the skin care composition with the effects of suppressing the mites and delaying the senescence has the obvious effect of improving the texture and the roughness of skin.
The proposed program is unique both in its delivery system and the development process. The program will be delivered in a computer game like format over a school-based intranet system (i.e., networked computers linked to a school-based server), which enables users to interact individually with the program and to share their experiences by receiving immediate feedback on both their own responses and those of their classmates' collective responses. The delivery of this computer-based programs assures fidelity of implementation. Each activity (component) ultimately included in the program will be continually developed and tested to assure that it is effective at changing the targeted theoretically based etiological mechanism (risk factor). Development will include an experimental assessment to evaluate the effectiveness of each component and only effective components will be included in the program. The 7th grade version of Click City®: Alcohol program will consist of 12 effective components delivered in six sessions over a three-week period. This will be followed by two 8th grade booster sessions, consisting of a total of 5 components delivered over a one-week period. Educational newsletters to parents and teacher guides will be developed to accompany the program. The investigators will conduct a randomized efficacy trial with 26 middle schools. Half of the schools will use the newly developed program and the other half will use the programs that they usually do to teach about Alcohol.
FIELD: medicine. SUBSTANCE: described are new intermediate products of camptotecine of formula I:   wherein R a  is chlorine atom, lower alkoxy group, R b  is hydrogen atoms, C 1-8  alkyl, hydroxy C 1-8  alkyl, C(O)H or group(a); R c  is group selected from formula II-IX, or R b  and R c  together form residue of formula   or   is chlorine atom or group C(O)OR 4 ; R 3  is hydrogen atom or benzyl; R 4  is C 1-8  alkyl; R 5  is hydrogen atom; R 6  is C 1-8  alkyl; R 7  is hydrogen atom. Compounds are active anticancer medicinals. Also described is method of preparing camptotecine (CPT-11) derivatives and related compounds. EFFECT: improved properties of the title compounds. 87 cl, 4 dwg
Healthy donors are patients undergoing cardio-vascular surgery for their usual support. During this surgery, 2 milliliters of the bone marrow will be collected, and analysed for the COSMOS study.
1,152,645. Rubella vaccine. MERCK & CO. Inc. 14 July, 1967 [22 May, 1967], No. 32603/67. Heading A5B. A rubella vaccine is prepared by isolating rubella virus from clinical material by inoculation of chick embryo or grivet monkey tissue culture and incubating at 30-38‹C.; successively passing the virus through culture media to attenuate the virus at least one of such passages being in media comprising minced and trypsinised 9-11 day old decapitated and amputated chick embryo culture in a cell growth medium at 30-38‹C., each passage being followed by infectivity titrations on sample harvests taken at 2-14 day intervals, the harvests being frozen until tested and re-inoculated in a culture medium if too virulent. The serial passages may include incubations in grivet monkey kidney cultures, embryonated hen's eggs or duck embryo tissue cultures.
Erosive Tooth Wear (ETW) is the loss of tooth structure without bacterial involvement. As the resulting loss of tooth structure is irreversible, an early evaluation of the multifactorial etiology, accurate diagnosis and regular follow-up are essential. The ETW is dynamic and its progression should be continuously monitored. A risk analysis table was developed to systematically record risk factors for ETW (Fig. 2). This allows ETW management to be integrated more efficiently into clinical practice and the progression to be documented over the years. If ETW is assumed, the risk analysis should be performed and updated at least every two years. In the assessment, risk-promoting and risk-inhibiting factors are marked, added together and compared. If the negative factors pre-dominate, measures should be taken to minimize the risk for ETW. The main purpose of the risk analysis is therefore to evaluate the individual etiology, coun-teract negative factors, promote positive factors and prevent progression.
FIELD: medicine. SUBSTANCE: invention relates to biologically active tonic agent that has [poly-(2,5-dihydroxyphenylene)]-4-thiosulfoacid sodium salt and vitamin addition. Agent is a solid form releasing carbon dioxide gas in dissolution and ready for using. Content of [poly-(2,5-dihydroxyphenylene)] -4-thiosulfoacid sodium salt in agent is 0.05-0.15 of mean oral single therapeutic dose and content of vitamin addition is the mean therapeutic dose, not less. Biologically active agent can has from two to six phenylene rings, it has sodium hydrocarbonate and pharmaceutically acceptable acid in solid form. Agent can has vitamin or polyvitamin preparation, ascorbic acid as vitamin addition and citric or tartaric acid as an acceptable acid. Invention provides development of tonic effect of agent after intake immediately and agent has minimal amount of olefin. EFFECT: enhanced effectiveness of agent. 2 cl, 1 dwg, 1 ex
Participants in this group will participate in 4-H programming as usual. They will have the opportunity to use the REAL media curriculum at the conclusion of the study.
The patients will be transplanted according to standard procedures by the institutional protocol. Median time of surgery is 7 hours and 20 minutes. Each surgical procedure will be performed by specialists at the Rikshospitalet liver transplantation team, which consists of seven specialists at the unit. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Complete clearance of the lymphatic tissue around the hepatoduodenal ligament. Frozen section is obtained from the distal end of the common bile duct. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.
Disclosed are systems and methods for automatic determination of one or more medical devices for vascular access prior to direct patient assessment. For example, a system can include a console and a display screen optionally integrated into the console. The console can include one or more processors and memory. The memory can include instructions configured to instantiate one or more processes when executed by the one-or-more processors for the automatic determination of the one-or-more medical devices for vascular access in accordance with a plurality of data inputs, various operating parameters, historical data, or a combination thereof. The automatic determination of the one-or-more medical devices can use at least logic, algorithms, machine learning including a machine-learning model trained with the historical data, artificial intelligence, or a combination thereof. The display screen can be configured to display the one-or-more medical devices recommended for vascular access.